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Cathelicidins are antimicrobial peptides from sheep (SMAP29 and SMAP34), rabbits (CAP11 and CAP18),
rodents (CRAMP), and humans (FALL39, LL37, and h/CAP18). In a broth microdilution assay against nine
ovine pathogens, SMAP29, SMAP34, mouse CRAMP, CAP18, CAP1831, CAP1828, CAP1822, and
CAP1821a were the most active, with MICs as low as 0.6 μg/ml. Other cathelicidins were less active. In lambs
with pneumonia, 0.5 mg of SMAP29 reduced the concentration of bacteria in both bronchoalveolar lavage
fluid and consolidated pulmonary tissues. Hence, the antimicrobial activity of SMAP29 suggests that it has
applications in the treatment of respiratory tract infections.
Disciplines
Pediatrics | Veterinary Pathology and Pathobiology
Comments
This article is from Antimicrobial Agents and Chemotherapy 45, no. 1 ( January 2001): 331–334, doi:10.1128/
AAC.45.1.331-334.2001.
Authors
Kim A. Brogden, V. C. Kalfa, Mark R. Ackermann, D. E. Palmquist, Paul B. McCray Jr., and B. F. Tack
This article is available at Iowa State University Digital Repository: http://lib.dr.iastate.edu/vpath_pubs/25
  
10.1128/AAC.45.1.331-334.2001. 
2001, 45(1):331. DOI:Antimicrob. Agents Chemother. 
Palmquist, P. B. McCray Jr. and B. F. Tack
K. A. Brogden, V. C. Kalfa, M. R. Ackermann, D. E.
 
Ovine Model of Pulmonary Infection
Respiratory Pathogens In Vitro and in an 
The Ovine Cathelicidin SMAP29 Kills Ovine
http://aac.asm.org/content/45/1/331
Updated information and services can be found at: 
These include:
REFERENCES
http://aac.asm.org/content/45/1/331#ref-list-1
This article cites 17 articles, 9 of which can be accessed free at:
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 
http://journals.asm.org/site/subscriptions/To subscribe to to another ASM Journal go to: 
 o
n
 February 25, 2013 by IO
W
A STATE UNIVERSITY
http://aac.asm
.org/
D
ow
nloaded from
 
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,
0066-4804/01/$04.0010 DOI: 10.1128/AAC.45.1.331–334.2001
Jan. 2001, p. 331–334 Vol. 45, No. 1
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
The Ovine Cathelicidin SMAP29 Kills Ovine Respiratory
Pathogens In Vitro and in an Ovine Model of
Pulmonary Infection
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Cathelicidins are antimicrobial peptides from sheep (SMAP29 and SMAP34), rabbits (CAP11 and CAP18),
rodents (CRAMP), and humans (FALL39, LL37, and h/CAP18). In a broth microdilution assay against nine
ovine pathogens, SMAP29, SMAP34, mouse CRAMP, CAP18, CAP1831, CAP1828, CAP1822, and CAP1821a were
the most active, with MICs as low as 0.6 mg/ml. Other cathelicidins were less active. In lambs with pneumonia,
0.5 mg of SMAP29 reduced the concentration of bacteria in both bronchoalveolar lavage fluid and consolidated
pulmonary tissues. Hence, the antimicrobial activity of SMAP29 suggests that it has applications in the
treatment of respiratory tract infections.
Innate host defenses in the respiratory tract of sheep are
currently being examined as models for airway bacterial clear-
ance (2), cystic fibrosis (2, 3, 10–13), and Pseudomonas aerugi-
nosa pneumonia (6, 7). SMAP29, a cathelicidin from sheep, is
also being considered as a therapeutic agent against microbial
infections (5, 9), including P. aeruginosa associated with
chronic respiratory inflammation in cystic fibrosis patients (14).
Although SMAP29 is highly effective against P. aeruginosa
PAO1 and other common gram-positive and gram-negative
organisms (14), its efficacy against a panel of pathogens orig-
inating from the same host species is unknown. Therefore, a
broth microdilution assay was used to obtain both MICs and
minimum bactericidal concentrations (MBCs) of SMAP29
against a panel of ovine pathogens (15, 18). SMAP34, mouse
CRAMP, rat CRAMP, FALL39, FF21, CAP18, and truncated,
congeners of CAP18 were included for comparison and syn-
thesized as previously described (14). Stock solutions of pep-
tides were diluted in 0.4% bovine serum albumin containing
0.02% acetic acid (0.16 to 80.00 mg/ml) and added to polypro-
pylene microtiter plates (Sigma, St. Louis, Mo.); 10 mM so-
dium phosphate buffer (pH 7.2) with 140 mM NaCl (PBS) was
added to control wells. Mueller-Hinton broth containing a
105-CFU/ml concentration of Mannheimia haemolytica serovar
1 (strain 82-25), 2, or 6; Pasteurella trehalosi serovar 4; Salmo-
nella enterica subsp. arizonae; ovine Pasteurella multocida sero-
var 3A (strain P-2062); Klebsiella pneumoniae ATCC 10031;
Corynebacterium pseudotuberculosis ATCC 19410; Staphylococ-
cus aureus; or P. aeruginosa PAO1 was added. Mueller-Hinton
broth was added to wells containing PBS and used as the plate
blank. After 24 and 48 h at 37°C, the optical density of bacterial
growth was determined (Spectromax Microplate Reader; Mo-
lecular Devices Corp., Sunnyvale, Calif.). The MIC (e.g., the
lowest concentration of peptide that reduced growth by more
than 50% compared to control wells) and the MBC (e.g., the
lowest concentration of peptide that prevented well growth)
were determined.
Peptides were active against PAO1, included as a susceptible
control, and these results (Tables 1 and 2) were similar to those
previously reported for other assays (14). Wide ranges of ac-
tivity against gram-negative bacteria were seen with mouse
CRAMP (MIC, 3.3 to 15.0 mg/ml), rat CRAMP (MIC, 5.0 to
20.0 mg/ml), FALL39 (MIC, 2.1 to .20.0 mg/ml), FF21 (MIC,
3.3 to $20.0 mg/ml), and SMAP34 (MIC, 5.0 to 11.7 mg/ml)
(Table 1). MBCs were comparable to the corresponding MICs.
SMAP29 (MIC, 0.6 to 2.5 mg/ml) and CAP18 (MIC, 1.3 to 10.0
mg/ml) had the highest activities. The activity of CAP18 con-
geners also varied, and CAP1831, CAP1828, CAP1822, and
CAP1821a were very active against gram-negative bacteria, but
the others were not (Table 2). All peptides were less active
against C. pseudotuberculosis and S. aureus (MIC, 10.0 to $20.0
mg/ml).
In CAP18, truncations of the N terminus did not adversely
affect the antimicrobial activity of congeners with a complete C
terminus (e.g., CAP1831 and CAP1828), and truncations of the
C terminus did not adversely affect the antimicrobial activity of
congeners with a complete N terminus (e.g., CAP1821a). How-
ever, a severe truncation of the N terminus (e.g., CAP1826) or
simultaneous truncations at both termini (e.g., CAP1821b,
CAP1819, CAP1818, CAP1817, CAP1815a, and CAP1815b) de-
creased antimicrobial activity. Unfortunately, no central region
with all of the antimicrobial activity could be identified. In-
stead, congeners needed to be at least 21 or more residues long
to be effective. For PAO1, this number could drop to a mini-
mum of 18 residues (e.g., CAP1818). Whether this size is re-
lated to the amphipathic structure of the peptide needed to
form pores or otherwise disrupt the cytoplasmic membrane is
not known.
* Corresponding author. Mailing address: Respiratory Diseases of
Livestock Research Unit, National Animal Disease Center, 2300 Day-
ton Ave., P.O. Box 70, Ames, IA 50010. Phone: (515) 663-7534. Fax:
(515) 663-7458. E-mail: kbrogden@nadc.ars.usda.gov.
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The high activity of SMAP29 in these assays suggested that
it might also be effective in vivo. To demonstrate this, 15 lambs,
approximately 60 to 70 lb, were lightly sedated for bronchos-
copy as previously described (1). Inocula were placed into the
dorsum of the caudal portion of the cranial lobe of the right
lung (pulmonary deposition site) in each animal. Two lambs in
group 1 and three lambs in group 2 received 10 ml of PBS with
0.25 mg of purified ovine pulmonary surfactant per ml (PBS-
PS). Five lambs in group 3 and five lambs in group 4 received
10 ml of M. haemolytica (2.5 3 108 CFU/ml in PBS-PS).
PBS-PS was used as a diluent to decrease atelectasis and fa-
cilitate pulmonary spreading (4, 17). At 24 h postinoculation,
lambs in group 1 and group 3 received an additional 10 ml of
PBS-PS at the same deposition site. Lambs in group 2 received
10 ml of PBS-PS with 100 mg of SMAP/ml, and those in group
4 received 10 ml of PBS-PS with 50 mg of SMAP29/ml.
At 48 h postinoculation, all lambs were euthanized, their
lungs were evaluated grossly, and total lung involvement was
calculated as previously described (1, 16). Bronchoalveolar
lavage (BAL) fluids and consolidated lung tissue were col-
lected for quantitative bacteriological culture, determination
of total leukocyte counts, and histopathological examination.
The extents of lymphocytic and/or neutrophilic infiltration, ne-
crosis, and collapse were scored as previously described (1),
with a maximum score of 4 for each category. The concentra-
tions of M. haemolytica in pulmonary tissues and fluids were
transformed [log10 (X 1 1)], and differences among groups was
assessed by one-way analyses of variance. When an analysis of
variance resulted in a significant F-test statistic, indicating
group differences, Duncan’s multiple-range test was used as
the multiple comparison procedure for detecting pairwise dif-
ferences among the treatment group means.
The lungs of lambs in groups 1 and 2 were free of gross
lesions and histopathology (Table 3). BAL fluids contained
means of 0.4 3 106 and 0.9 3 106 leukocytes/ml, respectively.
Bronchioles and surrounding alveoli contained minimal to
mild infiltrates of lymphocytes in the bronchiolar wall, but
there was no acute inflammatory response in the bronchioles
or alveoli.
The lungs of lambs in group 3 had extensive lesions charac-
terized by focal areas of consolidation with hemorrhage and
necrosis. BAL fluids contained a mean of 3.3 3 106 leukocytes/
ml. There were minimal multifocal lymphocytic peribronchio-
lar infiltrates, mild to suppurative bronchitis and/or pneumo-
nia, and minimal to moderate necrosis, hemorrhage, and
collapse. Four of five lambs had M. haemolytica in BAL fluid
(2.3 log10 CFU/ml), and all five lambs had organisms in con-
solidated pulmonary tissues (5.1 log10 CFU/g) collected from
the deposition site. (Table 3).
The lesions in the lungs of lambs in group 4 were not as
severe, and BAL fluids contained a mean of 4.9 3 106 leuko-
cytes/ml. Sections of bronchioles and surrounding alveoli
showed moderate numbers of lymphocytes in the bronchiolar
wall but no acute inflammatory response. Three of five lambs
had M. haemolytica in the BAL fluid (0.9 log10 CFU/ml), and
all of the lambs had lesser numbers of organisms in consoli-
dated pulmonary tissues (3.7 log10 CFU/g) collected from the
deposition site.
Previously, prevention or treatment of respiratory infections
with cathelicidins has not been fruitful. For example, CAP18
mixed with P. aeruginosa prior to intratracheal instillation in
mice significantly reduced pulmonary injury but did not reduce
the number of bacteria that had been instilled, nor did it
improve the survival of the infected mice (8). Interestingly,
CAP18 alone induced edema, suggesting that it had some
pulmonary toxicity (8). To eliminate these species differences
within the model, we established a homologous ovine model of
acute pneumonia using ovine SMAP29 against the ovine re-
spiratory pathogen M. haemolytica. SMAP29 alone was well
tolerated (group 2), and the 1.0-mg dose (twice the treatment
dose in group 4) did not induce any significant gross pathology,
histopathology, or inflammatory cell filtrates in BAL fluid.
Also, lambs treated with only a single dose of SMAP29 had
substantially lower gross pulmonary lesion scores, histopatho-
logical lesion scores, and concentrations of M. haemolytica in
BAL fluids and consolidated pulmonary tissues than untreated
lambs. Further studies will determine the optimal doses and
intervals of SMAP29 therapy.
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